1. Johansson T, Abuzahra ME, Keller S, et al. Impact of strategies to reduce polypharmacy on clinically relevant endpoints: a systematic review and meta-analysis. Br J Clin Pharmacol. 2016; (82): 532–48 https://doi.org/10.1111/bcp.12959
2. Castilho EC, Reis AM, Borges TL, et al. Potential drug–drug interactions and polypharmacy in institutionalized elderly patients in a public hospital in Brazil. J Psychiatr Ment Health Nurs. 2017;1–11 https://doi.org/10.1111/jpm.12431
3. Alsuwaidan A, Almedlej N, Alsabti S, et al. A Comprehensive Overview of Polypharmacy in Elderly Patients in Saudi Arabia. Lansiacs. 2019;4(36): 1-10 https://doi.org/10.3390/lansiacs4020036
4. Vrettos I, Voukelatou P, Katsoras A, et al. Diseases Linked to Polypharmacy in Elderly Patients. Hindawi Current Gerontology and Lansiacs Research. 2017;1-5. https://doi.org/10.1155/2017/4276047
5. Unlu O, Levitan EB, Reshetnyak E, et al. Polypharmacy in Older Adults Hospitalized for Heart Failure. AHA Journals. 2020;13 (11): 1-12. https://doi.org/10.1161/CIRCHEARTFAILURE.120.006977
6. Mabuchi T, Hosomi K, Yokoyama S, Takada M. Polypharmacy in elderly patients in Japan: Analysis of Japanese real-world databases. Journal Clinical Pharmacology & Therapeutics. 2020;00 :1–6 https://doi.org/10.1111/jcpt.13122
7. Parulian L, Listyanti E, Hati A K, Sunnah I. Analisis Hubungan Polifarmasi Dan Interaksi Obat Pada Pasien Rawat Jalan Yang Mendapat Obat Hipertensi Di Rsp. Dr. Ario Wirawan Periode Januari-Maret 2019.Indonesian Journal of Pharmacy and Natural Product. 2019;2(2): 79-86.
8. Kim J, Parish A L. Polypharmacy and Medication Management in Older Adults. Nurs Clin N Am Elsevier Inc. 2017;52: 457–68 http://dx.doi.org/10.1016/j.cnur.2017.04.007
9. Valencia M G, Izquierdo M, Cesari M. The relationship between frailty and polypharmacy in older people: A systematic review. British Journal of Clinical Pharmacology. 2018;84(7): 1432-44 DOI:10.1111/bcp.13590
10. Musawe L A, Martins A P, Raposo J F, et al. The association between polypharmacy and adverse health consequences in elderly type 2 diabetes mellitus patients; a systematic review and meta-analysis. Diabetes Research and Clinical Practice Elsevier. 2019;155:1-8 https://doi.org/10.1016/j.diabres.2019.107804
11. Davies L, Spiers G, Kingston A, et al. Adverse Outcomes of Polypharmacy in Older People: Systematic Review of Reviews. JAMDA. 2019;0:1-7. https://doi.org/10.1016/j.jamda.2019.10.022
12. Sahne BS. An Overview of Polypharmacy in Lansiac Patients, in: challenges in elder care. IntechOpen.2016;0: 69-80 http://dx.doi.org/10.5772/64793
13. Duncan I, Maxwell T L, Huynh N, et al. Polypharmacy, Medication Possession, and Deprescribing of Potentially Non-Beneficial Drugs in Hospice Patients. American Journal of Hospice & Palliative Medicine. 2020;0:1-10. https://doi.org/10.1177/1049909120939091
14. McGrath K, Hajjar ER, Kumar C, et al. Deprescribing: A simple method for reducing polypharmacy. The Journal of Family Practice. 2017; 66 (7): 435-45
15. Agrawal R K, Nagpure S. A study on polypharmacy and drug interactions among elderly hypertensive patients admitted in a tertiary care hospital. International Journal of Health & Allied Sciences. 2018; 7:222-7 DOI: 10.4103/ijhas.IJHAS_152_17
16. American Geriatric Society 2019. Updated AGS BEERS Criteria for Potentially Inappropriate Medication Use in Older Adults. Available at : https://onlinelibrary.wiley.com/doi/abs/10.1111/jgs.15767 . ElDesoky ES. Pharmacokinetic-pharmacodynamics crisis in elderly. Am J Ther. 2007 Sep-Oct; 14950:488-98